AUPH

Aurinia Pharmaceuticals Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$16.21

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %4 / %30

Non-compliant assets / Total market cap %31.7 / %30

Non-compliant revenue / Total income %4.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Website

Analysis (Turkish): AUPH Hissesi Caiz mi, Helal mi? Aurinia Pharmaceuticals Inc. Katılım Analizi